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Abstract
During a 12-year period, Dermabacter hominis was isolated from 21 clinical samples belonging to 14 patients attending a tertiary hospital in
Leon, Spain. Samples included blood cultures (14), peritoneal dialysis catheter exit sites (three), cutaneous abscesses (two), an infected
vascular catheter (one) and a wound swab (one). Identiﬁcation was made by API CoryneTM V2.0, BiologTM GP2 and 16S rRNA gene
ampliﬁcation. Six febrile patients had positive blood cultures (one, two or three sets) and all of them were treated with teicoplanin (two
patients), vancomycin, ampicillin plus gentamicin, amoxicillin/clavulanic acid and ciproﬂoxacin (one each). An additional patient with a single
positive blood culture was not treated, the ﬁnding being considered non-signiﬁcant. In the remaining seven patients the organism was
isolated from a single specimen and three of them received antimicrobial treatment (ciproﬂoxacin, ceftriaxone plus vancomycin and
amoxicillin/clavulanic acid). At least ten patients had several underlying diseases and conditions, and no direct mortality was observed in
relation to the isolated organism. All isolates were susceptible to vancomycin, rifampin and linezolid. Resistance to other antibiotics varied:
erythromycin (100%), clindamycin (78.5%), ciproﬂoxacin (21.4%) and gentamicin, quinupristin-dalfopristin, benzylpenicillin and imipenem
7.1% each. Thirteen isolates were highly resistant to daptomycin with MICs ranging from 8 to 48 (MIC90 = 32 mg/L); only one was
daptomycin-sensitive (MIC = 0.19 mg/L).
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Introduction
Dermabacter hominis, formerly known as coryneform bacteria
of Centers for Disease Control groups 3 and 5, is a facultative
anaerobic, catalase-positive, non-motile, glucose, maltose and
sucrose fermentative, irregular gram-positive bacillus. It
hydrolyses aesculin and decarboxylates ornithine and lysine,
and grows on nutrient and blood agar forming white, convex,
creamy or dry colonies of 1–1.5 mm diameter at 48 h in an
aerobic atmosphere, resembling coagulase-negative staphylo-
cocci [1–3]. It can be identiﬁed by conventional pheno-
type-based methods, including the API CoryneTM V2.0, and
matrix assisted laser desorption ionization-time of ﬂight mass
spectrometry system [2,4,5]. A conﬁrmatory test such as 16S
rRNA gene sequencing is also recommended [2,4].
Dermabacter hominis is considered a common colonizer
from human skin [1]. Operational taxonomic units with 99%
sequence identity to the 16S rDNA gene of D. hominis have
been identiﬁed in skin samples in the course of the Human
Microbiome Project [6,7] and in human gastrointestinal
specimens [8]. Furthermore, D. hominis has been isolated
from a variety of clinical specimens, such as blood cultures,
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abscesses, infected vascular grafts, bone, wound and eye
infections, peritoneal dialysis and joint ﬂuids [2,3,9–13].
Dermabacter hominis is usually susceptible to vancomycin,
teicoplanin and linezolid with variable susceptibility to benzyl-
penicillin, ampicillin, cephalosporins, ciproﬂoxacin, clindamycin,
erythromycin, gentamicin, tobramycin, amikacin, chlorampheni-
col, fusidic acid and rifampin [2,11,13–16]. Daptomycin, a
lipopeptide antibiotic, is usually very active against most
gram-positive organisms including members of the Corynebacte-
rium genus andmostdiphtheroids [4,17–19].However, very little
information exists on daptomycin activity against D. hominis
although a couple of communications to congresses suggest that
this organism could be daptomycin-resistant (Cercenado E,
Marın M, Gama B, Alcala L, Bouza Santiago E. Daptomycin-resis-
tant Dermabacter hominis: an emerging Gram-positive coryne-
form rod causing human infections. 23rd European Congress of
Clinical Microbiology and Infectious Diseases, abstract 0451;
Fernandez-Natal I, Saez-Nieto JA, Valdezate-Ramos S, et al.,
Daptomycin-resistant coagulase-negative Staphylococcus? No,
Dermabacter hominis. XVII Congress of the Spanish Society of
Infectious Diseases and Clinical Microbiology, abstract 473).
The aims of this study are to review clinical and epidemi-
ological characteristics of patients with D. hominis isolated
from diverse clinical samples. In addition, antimicrobial
susceptibility to a variety of antimicrobials has been deter-
mined with special attention to daptomycin activity.
Material and Methods
Clinical samples
Isolates were recovered from 14 blood cultures (BacT/
AlerTTM, bioMerieux, Marcy-l’Etoile, France), three peritoneal
dialysis catheter exit sites, two cutaneous abscesses, an
infected vascular catheter and a wound swab. These samples
were received in the clinical laboratory from January 2000 to
December 2012 and belonged to 14 patients attended in a
tertiary hospital in Leon, Spain.
Identiﬁcation
Isolates were identiﬁed by using conventional phenotypic
methods, API CoryneTM V2.0 (bioMerieux), and BiologTM GP2
(Biolog, Inc., Hayward, CA, USA). In addition, identiﬁcation
was conﬁrmed by 16S rRNA gene sequencing using a
previously reported method [20].
Epidemiological and clinical data
Regarding age, sex, underlying diseases and conditions,
antimicrobial treatment and outcome were retrospectively
recorded by reviewing clinical charts.
Antimicrobial susceptibility
Antimicrobial susceptibility was determined by the Etest
method on Mueller–Hinton sheep blood agar plates, incubated
at 37°C in aerobiosis for 24–48 h. The following Etest strips
(bioMerieux) were used: benzylpenicillin, ampicillin, cefotax-
ime, imipenem, gentamicin, ciproﬂoxacin, moxiﬂoxacin, tetra-
cycline, tigecycline, rifampin, chloramphenicol, cotrimoxazole,
erythromycin, clarithromycin, azithromycin, clindamycin,
quinupristin-dalfopristin, linezolid and vancomycin. Daptomy-
cin susceptibility was determined by using a calcium-supple-
mented MIC Test Strip (Lioﬁlchem s.r.l., Roseto degli
Abruzzi, Italy). The MICs of 11 antibiotics were categorized
as susceptible, intermediate and resistant following the
CLSI-M45-A-2012 document for coryneform organisms [21].
Resistance to daptomycin was deﬁned as MICs >1 mg/L.
Staphylococcus aureus ATCC 29213 and Enterococcus faecalis
ATCC 29212 served as controls. Phenotypic resistance to
macrolide—lincosamide—streptogramin B antibiotics (MLSB)
was determined by a previously reported method [22].
Results
One isolate from each patient was characterized. All isolates
were identiﬁed by API CoryneTM V2.0 with good to very good
scores (>99.7% ID) with the following proﬁles: 4570165
(n = 5), 4570765 (n = 5), 4570325 (n = 2) and 4570365
(n = 2). BiologTM GP2 identiﬁed all isolates with 85–100% of
proﬁles corresponding to the taxon. The results of 16S rRNA
gene sequences (fragments between 1360 and 1455 bp)
were compared with sequences available in databases using
BLAST, and they showed a homology of 99.3–99.9% with
D. hominis.
Table 1 presents the main epidemiological and clinical data
regarding patients, source and antimicrobial treatment. The
age of the patients ranged from newborn to 79 years (mean,
54.0 years) with a male/female rate of 10/4. Twelve cases were
considered to be hospital-related or healthcare-related and
only two were community-acquired. At least ten patients had
several underlying diseases and conditions (chronic renal
failure, peritoneal dialysis, haemodialysis, human immunodeﬁ-
ciency virus infection, chronic hepatitis, preterm rupture of the
membranes, lymphoma, lung cancer, cytotoxic treatment and
neutropenia). Seven bacteraemic patients were diagnosed after
one (two patients), two (three patients) and three (two
patients) positive blood cultures. Five of these patients were
treated with antibiotics that were proved to be active in vitro
against the isolate: teicoplanin (two patients); vancomycin,
amoxicillin/clavulanic acid and ampicillin plus gentamicin one
patient each. One patient received ciproﬂoxacin, later proven
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not to be active in vitro against the isolate and the remaining
patient did not receive antibiotics.
In the seven remaining patients the organism was isolated
in pure culture from a single clinical specimen. Exudates from
cutaneous abscesses, vascular catheter and wound swab
were Gram-stained and moderate numbers of polymorpho-
nuclear leucocytes and coryneform organisms were seen.
Three of the patients had positive peritoneal dialysis catheter
exit site samples and one of them was treated with an
antibiotic that was active in vitro against the isolate (cipro-
ﬂoxacin), whereas the other two patients did not receive any
antimicrobial treatment. One patient with a catheter infec-
tion and another one with a cutaneous abscess also received
antibiotics active in vitro against the isolates (ceftriaxone plus
vancomycin, and amoxicillin/clavulanic acid), the latter also
requiring surgical drainage of the abscess. There was not
enough clinical information regarding the other two patients.
No mortality directly related with isolation of D. hominis was
observed.
Table 2 presents the results of antimicrobial susceptibility
of 14 D. hominis isolates to 21 antimicrobials. All isolates were
susceptible to vancomycin, rifampin and linezolid. No resis-
tance to tetracycline was detected although three isolates fell
into the intermediate category. Eleven isolates were highly
resistant to erythromycin and clindamycin (MICs >256 mg/L),
and only one of them was resistant to quinupristin-dalfopristin.
Low-level resistance to erythromycin (MICs 1.5–2 mg/L) was
detected in three isolates, which were all susceptible to
clindamycin and quinupristin-dalfopristin. Resistance to other
antibiotics varied: ciproﬂoxacin (21.4%); gentamicin, quinupri-
stin-dalfopristin, benzylpenicillin and imipenem 7.1% each.
Thirteen isolates were highly resistant to daptomycin with
MICs ranging from 8 to 48 (MIC90 = 32 mg/L) whereas only
one was daptomycin-sensitive (MIC = 0.19 mg/L).
Although there are no deﬁned susceptibility breakpoints for
many of the other tested antibiotics, the low MIC values
obtained in all isolates for teicoplanin (<0.19 mg/L), tigecycline
(<0.5 mg/L), and in 11 isolates for ampicillin, cefotaxime and
moxiﬂoxacin (<1 mg/L) should be noted. The results for
clarithromycin and azithromycin were similar to those of
erythromycin. Seven isolates had chloramphenicol MICs
<1 mg/L. On the other hand 12 isolates presented MICs
>32 mg/L for cotrimoxazole.
Discussion
Dermabacter hominis is the only recognized species of the
Dermabacter genus and it can be easily identiﬁed by phenotypic
conventional methods, including the API CoryneTM V2.0 system
[2,4] and matrix-assisted laser desorption/ionization–time of
ﬂight mass spectrometry [5]. Our data, together with the
published information [2,10–13], indicate that the predominant
API CoryneTM proﬁles for D. hominis are 4570365, 4570765
and 4570165. Identiﬁcation of D. hominis by using the BiologTM
system proved to be useful and reliable. As widely demon-
strated for other organisms, including members of the
Corynebacterium genus and coryneforms [2,4,20], the study of
the 16S rRNA gene sequence conﬁrmed phenotypic identiﬁ-
cation.
We have isolated D. hominis from a variety of clinical
samples including 14 blood cultures belonging to seven
patients. Among the seven bacteraemic patients, ﬁve were
immunosuppressed and one had a lung infection secondary to
bronchoaspiration, and all were treated with antibiotics. The
remaining patient who had a single positive blood culture did
not receive antimicrobial treatment because the culture was
not considered clinically relevant.
TABLE 1. Data on patients with Dermabacter hominis isolation
No. Sex, age (years) Source (n) Underlying disease(s) Diagnosis Antimicrobial treatment
1 M, 43 Blood (2)a HIV-infected, chronic hepatitis, lymphoma,
cytotoxic drugs
Neutropenic fever Teicoplanin
2 M, 54 Blood (1)b No Viral meningitis No
3 M, 53 Blood (2)a Lung cancer, cytotoxic drugs Neutropenic fever Teicoplanin
4 F, 79 Blood (3)a Epilepsy Bronchoaspiration, fever Amoxicillin/clavulanic acid
5 M, 29 Blood (3)a Lymphoma Pyelonephritis, fever Ciproﬂoxacin
6 M, newborn Blood (1)a Preterm rupture of the membranes Chorioamnionitis, fever Ampicillin + gentamicin
7 M, 65 Blood (2)c Chronic renal insufﬁciency, haemodialysis Fever Vancomycin
8 F, 56 PDCES (1)c Chronic renal insufﬁciency, peritoneal dialysis Exit-site infection Ciproﬂoxacin
9 F, 73 PDCES (1)c Chronic renal insufﬁciency, peritoneal dialysis Exit-site control No
10 M, 66 PDCES (1)c Chronic renal insufﬁciency, peritoneal dialysis Exit-site infection, fever No
11 M, 77 Vascular catheter (1)c Chronic renal insufﬁciency, haemodialysis,
amyloidosis
Fever Ceftriaxone + vancomycin
12 M, 59 Abscess (1)d Unknown Cutaneous abscess Unknown
13 M, 59 Wound swab (1)a Chronic osteomyelitis Unknown Unknown
14 M, 44 Abscess (1)d No Cutaneous abscess Amoxicillin/clavulanic acid
HIV, human immunodeﬁciency virus; PDCES, peritoneal dialysis catheter exit site.
Probably acquisition of the organism: ahospital; bhospital (probable contamination); chealth care (dialysis); dcommunity.
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In the seven remaining patients, the organism was isolated
from a single clinical specimen. Three of these patients
received antibiotics that were active in vitro against the isolate,
plus surgical drainage in the case of a cutaneous abscess.
Although the clinical information is not complete for all
patients, the data obtained support that D. hominis can be an
opportunistic microorganism usually associated with very low
mortality, in agreement with what has been previously
reported [2,3,9–12]. Nevertheless, a fatal septicaemia in an
immunosuppressed patient has been reported [13].
The antimicrobial susceptibility of D. hominis is variable but
it has always been uniformly susceptible to vancomycin and
linezolid [2,11,13–16], which is also conﬁrmed in the present
study. We have not found resistance to rifampin and tetracy-
cline, and the rate of benzylpenicillin, imipenem, quinupri-
stin-dalfopristin resistance was very low (7.1%). Moderate
resistance was found for ciproﬂoxacin (21.4%). The high rate
of erythromycin and clindamycin resistance as well as the
results with quinupristin-dalfopristin suggests that resistance
to MLSB antibiotics is mainly constitutive, probably due to the
presence of the erm gene in 78.5% of our isolates.
The very recently established draft genome sequence of
isolate no. 5 (our unpublished data) led to the detection of the
corynebacterial erm(X) gene in this strain, explaining the
resistance against antimicrobials of the MLS class [23]. The
genome of isolate no. 5 also contains the cmx transporter gene
for chloramphenicol resistance, the strAB tandem genes for
streptomycin resistance [23] and the sul1 gene encoding a
dihydropteroate synthase that can confer resistance to a broad
spectrum of sulphonamides [24]. The gyrA gene contains the
deduced sequence motif FAIYD in the quinolone-resis-
tance-determining region, which might be associated with
ciproﬂoxacin, moxiﬂoxacin and levoﬂoxacin resistance [25].
The high rate of daptomycin-resistance is remarkable and it
contrasts with the wide and powerful activity of this drug
against most gram-positive organisms, including S. aureus,
enterococci, members of the Corynebacterium species and
coryneforms [4,16–19]. Although daptomycin’s mechanism of
action has not been fully elucidated, it seems to act by
insertion into the bacterial cell membrane in a calcium-depen-
dent manner, resulting in rapid membrane depolarization [26].
The addition of ionized calcium is highly recommended for in
vitro testing of daptomycin, as the MICs are much lower when
a concentration similar to the one found in human serum is
incorporated [17,18]. All except one of our D. hominis isolates
presented high daptomycin MICs in spite of having been tested
in calcium-supplemented conditions. This emphasizes the
relevance of our ﬁndings. Our report conﬁrms what had been
communicated to congresses on daptomycin resistance in this
organism but it also presents what we believe is the ﬁrst
report of a daptomycin-susceptible D. hominis strain.
Acquired resistance to daptomycin in gram-positive organ-
isms is rare but it is being increasingly reported in relation to
the use of this drug [27–29]. However, resistance to dapto-
mycin in D. hominis is very common and it seems to be
unrelated to the use of this antibiotic. The whole-genome
sequencing of an isogenic, clinical and laboratory-derived
S. aureus strain, which had been exposed to daptomycin, has
been performed and found a point mutation in genes coding
for membrane phospholipids [26]. On the other hand, electron
microscopy and lipid membrane studies have shown that
daptomycin non-susceptible S. aureus strains had a thicker cell
TABLE 2. Antimicrobial susceptibility of 14 Dermabacter hominis isolates (MICs in mg/L)
Antibiotic
Isolate
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Benzylpenicillin 0.064 0.064 0.125 0.094 1.5 0.125 0.25 0.5 0.5 2 6 2 0.19 0.094
Ampicillin 0.064 0.25 0.5 0.5 2 0.38 2 1 0.75 0.5 6 0.5 0.25 0.125
Cefotaxime 0.047 0.064 0.094 0.064 3 0.19 0.064 0.125 0.25 3 4 0.094 0.125 0.047
Imipenem 0.25 0.5 0.75 0.5 >32 0.5 0.38 0.75 0.75 2 2 0.38 0.75 0.38
Gentamicin 0.5 0.75 0.75 0.75 >256 1 4 1 1.5 2 3 0.75 1 0.38
Ciproﬂoxacin 0.75 0.5 1 0.75 >32 1.5 1 1.5 2 >32 >32 0.75 1.5 0.5
Moxiﬂoxacin 0.064 0.094 0.125 0.094 >32 0.125 0.125 0.19 0.19 4 12 0.094 0.12 0.094
Tetracycline 0.125 0.25 0.5 0.25 4 0.38 6 1.5 0.75 6 8 0.19 1 0.5
Tigecycline 0.125 0.094 0.125 0.125 0.19 0.094 0.38 0.19 0.25 0.19 0.5 0.064 0.19 0.094
Rifampin 0.006 0.006 0.004 0.006 0.006 0.003 0.004 0.006 0.006 0.006 0.006 0.006 0.006 0.004
Chloramphenicol 1 1.5 0.32 1.5 12 1.5 1 2 12 16 1 1 2 24
Cotrimoxazole >32 >32 >32 >32 >32 >32 0.25 >32 >32 >32 >32 >32 >32 0.25
Erythromycin >256 >256 >256 >256 >256 2 >256 >256 1.5 >256 >256 >256 1.5 >256
Clarithromycin >256 >256 >256 >256 >256 1.5 >256 >256 2 >256 >256 >256 2 >256
Azithromycin >256 >256 >256 >256 >256 3 >256 >256 3 >256 >256 >256 3 >256
Clindamycin >256 >256 >256 >256 >256 0.064 >256 >256 0.125 >256 >256 >256 0.094 >256
Quinupristin-
dalfopristin
0.75 0.75 0.38 0.5 >32 0.25 1 0.38 0.38 1.5 2 0.5 0.38 1
Linezolid 0.5 1 0.75 0.75 0.25 0.38 0.38 1.5 1 0.75 0.38 0.75 0.75 0.75
Vancomycin 0.38 0.38 0.38 0.38 0.75 0.38 0.38 0.5 0.38 0.38 0.5 0.38 0.38 0.38
Teicoplanin 0.19 0.125 0.19 0.19 0.125 0.064 0.094 0.19 0.064 0.125 0.125 0.19 0.047 0.125
Daptomycin 16 16 24 16 16 8 32 32 8 32 48 16 32 0.19
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wall and an increase in membrane lysyl-phosphatidylglycerol
[27]. In enterococci, mutations in genes encoding a putative
membrane protein and a GdpD-family protein are necessary
and sufﬁcient for the development of resistance to daptomy-
cin during the treatment of vancomycin-resistant strains [28].
In daptomycin non-susceptible isolates of Enterococcus fae-
cium, a higher net surface charge and an increased septum
formation have been found compared with susceptible
isolates [29].
Enzymatic inactivation of daptomycin, as recently shown in
some actinomycetes, could also be responsible for resistance
owing to ring hydrolysis, which leads to drug linearization, and
deacylation of the lipid tail [30]. Comparative genomics and
lipid membrane studies of D. hominis could allow new insights
into the mechanisms that convey resistance to daptomycin in
this organism.
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